Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
TBPH Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Theravance Biopharma, Inc.NASDAQ: TBPH
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 17.2% from a year ago
Property, plant & equipment (net) stood at $28.54M at the end of Q1 FY2026, down 17.2% from a year earlier and down 5.7% from the prior quarter. Over 3 fiscal years it compounded at -16.5% a year.
Context
- Property, plant & equipment (net) amounted to 6.0% of total assets at the end of Q1 FY2026, down 4.0 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -17.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 30.27M USD
- Year-over-year change
- -15.4%
- 4-year CAGR
- -13.2%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.27M | -15.4% |
| FY2024 | 2024-12-31 | 35.77M | -21.1% |
| FY2023 | 2023-12-31 | 45.36M | -12.8% |
| FY2022 | 2022-12-31 | 52M | -2.5% |
| FY2021 | 2021-12-31 | 53.35M | — |
Property, Plant & Equipment (Net) vs competitors
How TBPH compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -17.2% is the 8th highest of 9, against a peer median of -8.1%.
- Property, plant & equipment (net) amounts to 6.0% of total assets for TBPH, versus a peer median of 4.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | €133.75M EUR | -13.3% | -3.6% | 35.9% | |
| Mar 2026 | $113.92M USD | -5.3% | -14.5% | 11.1% | |
| Mar 2026 | $53.1M USD | -4.5% | -6.6% | 7.2% | |
| Dec 2025 | $50.33M USD | -5.3% | -1.9% | 15.1% | |
| Mar 2026 | $28.54M USD | -17.2% | -16.5% | 6.0% | |
| Mar 2026 | $6.66M USD | -10.8% | +24.8% | 1.6% | |
| Mar 2026 | $1.72M USD | -14.0% | +90.3% | 0.6% | |
| Mar 2026 | $1M USD | -74.0% | -43.6% | 0.2% | |
| Mar 2026 | $370K USD | +208.3% | -54.6% | 0.1% | |
| Peer median (excluding TBPH) | — | -8.1% | -5.1% | 4.4% | |
Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89.96M | 298.17M | 39.55M | 37.8M | 167.81M |
| Short-term Investments | 83.51M | 29.31M | 62.88M | 50.55M | 147.55M |
| Net Receivables | 57.6M | 16.79M | 17.47M | 68.44M | 95.54M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.56M | 7.68M | 11.6M | 4.2M | 7.56M |
| Total Current Assets | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M |
| Property, Plant & Equipment (Net) | 53.35M | 52M | 45.36M | 35.77M | 30.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 68.37M | 0 | 0 | 0 | 14.35M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.23M | 201.94M | 203.1M | 157.32M | 22.5M |
| Total Non-current Assets | 124.95M | 253.94M | 248.46M | 193.09M | 67.11M |
| Total Assets | 374.82M | 607.4M | 382M | 354.16M | 485.57M |
| Account Payables | 3.1M | 1.55M | 1.52M | 2.24M | 2.57M |
| Short-term Debt | 17.44M | 0 | 0 | 0 | 10.95M |
| Tax Payables | 0 | 0 | 0 | 5.85M | 0 |
| Deferred Revenue | 98K | 24K | 0 | 0 | 0 |
| Other Current Liabilities | 25.15M | (24K) | 12.88M | 0 | 6.91M |
| Total Current Liabilities | 58.59M | 28.72M | 24.77M | 32.09M | 38.3M |
| Long-term Debt | 599.39M | 0 | 0 | 0 | 32.8M |
| Deferred Tax Liabilities | 240K | 0 | 0 | 0 | 85.68M |
| Deferred Revenue (Non-current) | 310K | 192K | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.18M | 91.29M | 99M | 107.42M | 313K |
| Total Non-current Liabilities | 654.81M | 136.89M | 144.24M | 146.53M | 150.55M |
| Total Liabilities | 713.39M | 165.6M | 169M | 178.62M | 188.85M |
| Common Stock | 1K | 1K | 0 | 0 | 1K |
| Retained Earnings | (1.73B) | (853.91M) | (909.1M) | (965.52M) | (859.63M) |
| Accumulated OCI | (0) | (15K) | (65K) | 7K | 61K |
| Other Stockholders Equity | 0 | 0 | (0) | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (338.57M) | 441.8M | 213M | 175.55M | 296.72M |
| Total Debt | 669.52M | 52.16M | 49.16M | 49.82M | 75.5M |
| Net Debt | 579.56M | (246.01M) | 9.61M | 12.02M | (92.31M) |
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.